Levetiracetam: Nursing Drug Guide, Psychiatric Safety & NCLEX Review
Healthcare medication guide: monitor new irritability, aggression, and suicidal thoughts after every dose change; adjust for renal function; never stop abruptly without a seizure plan; and teach families what to report immediately.
Levetiracetam may cause behavioral abnormalities and psychotic symptoms—including irritability, aggression, anger, anxiety, and depression. Like all antiepileptic drugs, levetiracetam increases the risk of suicidal thoughts or behavior. Monitor patients for psychiatric signs and symptoms, especially after dose changes and in the first weeks of therapy. Avoid abrupt withdrawal, which can increase seizure frequency and status epilepticus; adjust dosing for renal impairment per Table 1 in prescribing information.
📋 Contents
⚡ Quick facts
💡 Key takeaway
After every dose change, ask whether irritability, aggression, or mood shifts are new—and screen for suicidal thoughts or behavior. Renal dosing and gradual withdrawal matter too, but missing psychiatric toxicity is the bedside error that harms patients on levetiracetam.
Most common brand names
Levetiracetam is available as immediate-release tablets, extended-release tablets (Keppra XR, Elepsia XR), oral solution, and orally disintegrating tablets (Spritam). Verify the specific formulation on the MAR—extended-release products are dosed once daily, while standard tablets and oral solution are usually twice daily.
Common brand names include Keppra, Keppra XR, Spritam, Roweepra, and Elepsia XR. Levetiracetam is also supplied as a generic antiepileptic drug (AED). Do not confuse it with other “lev-” anticonvulsants (e.g., lamotrigine) during medication reconciliation.
Why we give it — Indications
Levetiracetam is a widely used AED for partial-onset and generalized seizure disorders. Nurses see it on neurology, med-surg, psychiatric, and adolescent units—often after dose titration when behavioral monitoring matters most.
| Use | Detail |
|---|---|
| Partial-onset seizures | Indicated for treatment of partial-onset seizures in patients 1 month of age and older per DailyMed tablet labeling. |
| Juvenile myoclonic epilepsy (adjunct) | Adjunctive therapy for myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. |
| Primary generalized tonic-clonic seizures (adjunct) | Adjunctive therapy for primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy—often part of broader epilepsy management. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown per prescribing information. In vitro and in vivo studies suggest binding to the synaptic vesicle protein SV2A, which may modulate neurotransmitter release and decrease abnormal neuronal excitability. Levetiracetam is not a traditional sodium-channel blocker like carbamazepine or phenytoin, and it has low plasma protein binding—clinically significant displacement interactions are unlikely.
Dosing overview
Adults 16 years and older typically start at 500 mg twice daily, with increases of 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily (maximum 3000 mg/day). Dosing must be verified against the current order, formulation (immediate-release vs extended-release), age, weight (pediatrics), and renal function.
Table 1 — Adult renal dose adjustment (DailyMed)
Dose and interval below apply to immediate-release levetiracetam tablets. Calculate creatinine clearance adjusted for body surface area before selecting a regimen.
| Renal function group | Creatinine clearance (mL/min/1.73 m²) | Dosage (mg) | Frequency |
|---|---|---|---|
| Normal | > 80 | 500 to 1500 | Every 12 hours |
| Mild impairment | 50–80 | 500 to 1000 | Every 12 hours |
| Moderate impairment | 30–50 | 250 to 750 | Every 12 hours |
| Severe impairment | < 30 | 250 to 500 | Every 12 hours |
| ESRD on dialysis | — | 500 to 1000* | Every 24 hours* |
On a small screen, swipe or scroll sideways to see the full table.
*Following dialysis, a supplemental dose of 250 to 500 mg is recommended per Table 1.
Missed dose: If only a few hours have passed, take the missed dose as soon as remembered; if almost time for the next dose, skip the missed dose and continue the regular schedule. Do not double doses.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption / peak | Rapid; peak plasma concentration in about 1 hour (fasted); food delays Tmax by ~1.5 h and lowers Cmax by 20% without changing extent of absorption | May give with or without food; behavioral changes can emerge within days of titration—do not assume delayed onset means low risk |
| Half-life | ~7 ± 1 hours in adults; longer in elderly and shorter in young children per labeling | Twice-daily dosing for immediate-release; steady state after ~2 days of BID dosing |
| Elimination | ~66% renally excreted unchanged; clearance correlates with creatinine clearance | Trend serum creatinine and apply Table 1 in chronic kidney disease or acute kidney injury |
| Protein binding | <10% bound to plasma proteins | Low interaction potential via protein binding displacement |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review baseline and current mood, behavior, and psychiatric history—including prior depression or suicidal ideation
- Confirm renal function and whether Table 1 adjustment is reflected on the MAR after any creatinine change
- Perform neurological assessment and seizure precautions; know rescue benzodiazepine orders (e.g., diazepam) per protocol
- Screen for new or worsening agitation, confusion, or altered mental status after each dose change
Contraindications
- Known hypersensitivity to levetiracetam (anaphylaxis and angioedema reported)
Important warnings (labeling)
- Behavioral abnormalities and psychotic symptoms — irritability, aggression, hostility, anxiety, emotional lability; monitor psychiatric signs and symptoms
- Suicidal behavior and ideation — class warning for AEDs; monitor for depression, suicidal thoughts/behavior, and unusual mood or behavior changes as early as one week after initiation
- Serious dermatologic reactions — SJS/TEN and DRESS reported; discontinue at first sign of rash unless clearly unrelated
- Withdrawal seizures — avoid abrupt discontinuation; taper gradually unless a serious adverse reaction requires rapid withdrawal per prescriber
Selected interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Other CNS depressants | Additive sedation and psychomotor impairment possible | Assess sedation, fall risk, and safe mobility; reinforce seizure precautions |
| Oral contraceptives | Levetiracetam 500 mg BID did not alter ethinyl estradiol/levonorgestrel PK in labeling study | Still verify contraception counseling per prescriber; do not assume all formulations were studied |
| Renally cleared drugs | Levetiracetam clearance decreases as creatinine clearance falls | Recalculate Table 1 dosing when renal function changes; coordinate with pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral (tablets, oral solution, Spritam orally disintegrating tablets). Extended-release products are taken once daily; immediate-release tablets and solution are usually twice daily.
- May take with or without food per labeling
- Swallow immediate-release and extended-release tablets whole; do not crush or chew unless pharmacy approves a specific formulation for enteral use
- Oral solution: use only the calibrated device supplied; do not use household spoons
- Spritam: follow manufacturer directions for dissolving on the tongue or in liquid—do not swallow conventional tablets whole if Spritam is ordered
- Follow institutional medication administration and seizure-precaution protocols on every dose
Expected therapeutic response
- Decreased seizure frequency or severity over weeks of therapy—not necessarily after the first dose
- Stable level of consciousness without new behavioral toxicity when dose is appropriate
- Patient and family can describe what to report (mood, aggression, suicidal thoughts) and understand that levetiracetam controls but does not cure epilepsy
Red flags — Stop and act
Psychiatric and behavioral toxicity can appear within days of a dose increase. Escalate immediately when safety is threatened.
- New or worsening suicidal thoughts, self-harm statements, or giving away possessions
- Severe agitation, aggression, violent behavior, or psychotic symptoms (hallucinations, paranoia)
- Generalized tonic-clonic seizure, prolonged seizure, or repeated seizures without return to baseline—activate seizure emergency protocol
- Rash with fever, facial swelling, lymphadenopathy, or mucosal involvement (possible SJS/TEN or DRESS)
- Anaphylaxis or angioedema after a dose
- Patient or caregiver plans to stop all AED doses abruptly without prescriber guidance
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Somnolence, dizziness, weakness | Common in clinical trials | Assess fall risk; bed alarm and supervision as indicated; avoid driving until prescriber clears |
| Behavioral symptoms (irritability, aggression, hostility, anxiety, depression) | Non-psychotic behavioral symptoms reported more often than placebo (adults ~13%, pediatrics higher in labeling) | Document onset relative to dose changes; notify prescriber; implement safety precautions |
| Psychotic symptoms | Reported in labeling | Urgent psychiatric/neurology escalation; do not leave patient alone if violent or disorganized |
| Suicidal ideation / behavior | AED class warning | Immediate safety assessment and prescriber notification; follow facility suicide-risk protocol |
| Serious skin reactions (SJS/TEN, DRESS) | Rare; potentially fatal | Stop drug; urgent evaluation; do not rechallenge |
| Coordination difficulty | Post-marketing and trial reports | Complete fall risk assessment; assist with ambulation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
There is no specific antidote for levetiracetam overdose per labeling. The highest dose in clinical development was 6000 mg/day; post-marketing overdoses have included somnolence, agitation, aggression, decreased consciousness, respiratory depression, and coma.
Management
- Supportive care: airway, breathing, circulation; continuous monitoring
- Consider gastric decontamination if indicated and not contraindicated
- Standard hemodialysis removes approximately 50% of levetiracetam in 4 hours—may be considered with significant overdose or renal impairment per clinical team
- Contact local poison control / toxicology per facility protocol
Use local poison control or medical toxicology services per facility protocol for overdose guidance. Do not rely on country-specific emergency numbers in patient-facing teaching—follow your institution’s escalation pathway.
Look-alike / sound-alike and error prevention
- Levetiracetam vs lamotrigine — similar “lev-” prefix; different monitoring (rash/Stevens-Johnson risk vs behavioral toxicity emphasis)
- Keppra vs Keppra XR — verify once-daily extended-release vs twice-daily immediate-release
- Levetiracetam vs Spritam — Spritam is an orally disintegrating tablet with distinct administration steps
- Oral solution concentration — use calibrated oral syringe; mg vs mL errors are high-risk
- Duplicate AED therapy — confirm whether levetiracetam is adjunctive or monotherapy during reconciliation
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Behavior checks | After every titration, ask about irritability, anger outbursts, sleep, and suicidal thoughts—compare to pre-change baseline. |
| Food timing | May give with or without food; note food slightly delays peak without changing total absorption. |
| Renal labs | Recheck dosing when creatinine rises; ESRD patients need dialysis-day supplemental dose per Table 1. |
| Hepatic dosing | No adjustment per labeling—even with mild–moderate hepatic impairment. |
| Commonly missed | Attributing new aggression to “teen behavior” instead of AED toxicity after a recent dose increase. |
| Ask pharmacy when | Renal function changes, formulation switch (IR ↔ XR), enteral tube administration, or interacting sedatives added. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Adolescents and young adults | Higher rates of behavioral adverse effects reported in pediatric trials; irritability after titration is a common nursing concern—involve family in safety planning. |
| History of depression or prior suicidal behavior | AED class suicidality warning applies; closer mood monitoring and documented safety plans. |
| Renal impairment / dialysis | Reduced clearance; mandatory Table 1 adjustment and post-dialysis supplemental dose when on hemodialysis. |
| Older adults | Longer half-life and lower clearance with age-related renal decline; behavioral and sedation effects may be pronounced. |
| Pregnancy | Plasma levels may fall during pregnancy (especially third trimester); requires close therapeutic monitoring. Use only if benefit justifies potential fetal risk per labeling. |
| Lactation | Excreted in human milk; balance breastfeeding benefits with maternal clinical need and potential infant effects per prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Seizure frequency, type, duration, and postictal course
- Mood, behavior, sleep, and suicidal ideation—especially after initiation and each dose increase
- Renal function (serum creatinine, estimated clearance) for Table 1 dosing
- Sedation, gait, and fall risk
- Skin for rash, mucosal lesions, or systemic hypersensitivity signs
Document
- Dose, formulation, route, time, and any titration step completed
- Behavioral baseline and changes with direct quotes when safety-related
- Patient/family teaching on AED suicidality warning and who to call
- Renal adjustment calculations and pharmacy verification when applicable
Patient teaching
- Take levetiracetam exactly as prescribed; do not stop suddenly—stopping abruptly can worsen seizures
- Antiepileptic medicines may increase suicidal thoughts or actions in a small number of people—report new depression, anxiety, irritability, aggression, or thoughts of self-harm immediately
- Caregivers should watch for mood and behavior changes, especially in the first weeks after a dose change
- Report rash, facial swelling, trouble breathing, or severe dizziness
- Do not drive or operate machinery until you know how the medicine affects you
- For overdose or accidental ingestion, seek emergency care and contact local poison control / toxicology per facility protocol
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to levetiracetam or active anaphylaxis/angioedema
- New serious rash, mucosal lesions, or suspected SJS/TEN or DRESS
- Active suicidal intent, severe aggression, or psychosis requiring urgent psychiatric evaluation
- Order does not reflect required Table 1 renal adjustment when creatinine clearance is reduced
- Patient plans to discontinue abruptly without a taper or alternate seizure plan
- Repeated seizures or status epilepticus—hold routine oral dose and follow emergency seizure protocol while treating acute event
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Levetiracetam is not on typical ISMP high-alert medication lists, but psychiatric and behavioral toxicity after titration is a leading preventable harm story on neurology and adolescent units. Build mood and safety checks into every administration pass—not only seizure counts.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right formulation (IR vs XR vs Spritam)
- Compare today’s behavior to pre-titration baseline; ask about irritability, anger, and suicidal thoughts
- Verify renal dose matches latest creatinine clearance when impairment is present
- Confirm seizure precautions and rescue medication availability per order set
2. High-alert and safety badge
Not an ISMP high-alert medication — psychiatric monitoring emphasisLabeling highlights behavioral abnormalities, psychotic symptoms, and AED-class suicidal behavior warnings. Treat dose changes with the same structured monitoring rigor used for high-risk drugs: documented mood screen, family engagement, and prescriber notification triggers.
3. Clinical workflow: hold and question rules
- After any titration, if irritability or aggression is new, notify neurology/psychiatry before giving the next increased dose
- If creatinine rises, hold and request pharmacy Table 1 adjustment before resuming
- If patient wants to stop the drug, escalate for taper plan—do not simply discontinue at bedside
4. Critical teach-back questions
- “What mood or behavior changes should you report while on levetiracetam?” (Patient/caregiver should name irritability, aggression, depression, suicidal thoughts, or unusual behavior—especially after dose changes.)
- “What happens if you stop this medicine suddenly?” (Patient should state seizures may worsen and they must follow prescriber taper instructions.)
5. Care coordination
Pharmacist: Renal Table 1 adjustment, formulation changes, interaction review, and overdose/dialysis guidance
Neurology / psychiatry: New behavioral toxicity, suicidal ideation, psychosis, or need to change AED regimen
🧠 Quick mental checklist
- Was the dose increased in the last 1–2 weeks—and is today’s irritability new?
- Any suicidal statements, aggression, or psychotic symptoms since the last dose?
- Does renal dosing still match the latest creatinine clearance?
- Is the patient on the correct formulation (BID vs daily XR)?
- If levetiracetam is stopped, is there a taper and rescue seizure plan?
Levetiracetam NCLEX practice questions
Practice NCLEX-style clinical judgment practice for levetiracetam psychiatric safety using a tabbed adolescent case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), trend interpretation (SATA), matrix urgency sorting, clinical judgment (MCQ), and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Levetiracetam 500 mg PO BID — given 0800, 2000 yesterday
- Three days ago: dose increased to levetiracetam 750 mg PO BID per neurology
- Lorazepam 1 mg PO PRN seizure cluster — not given in last 24 h
- 0900 dose due; nurse reviewing tabs before administration
- Admission: serum creatinine 0.8 mg/dL; eGFR 118 mL/min/1.73 m²
- Today: serum creatinine 0.9 mg/dL; eGFR 110 mL/min/1.73 m² (normal renal function)
- No hepatic panel ordered — hepatic dose adjustment not required per labeling
- T 36.8 °C; HR 78; BP 118/72; RR 16; SpO₂ 99% on room air
- Pain 0/10; patient alert and oriented ×4
- No seizure activity observed in last 8 h
- 19-year-old with focal epilepsy; hospitalized after increased seizure frequency at home
- Mother at bedside: patient “not himself” since dose increase—yelling, slamming doors, irritable
- Patient denies suicidal thoughts but states “everyone is annoying me”
- Last seizure: brief focal episode 2 days ago; no loss of consciousness
- Plan: neurology rounding at 1100; 1:1 observation not yet ordered
Answer key & rationale
Frequently asked questions
What behavioral changes should nurses watch for on levetiracetam?
Prescribing information warns that levetiracetam may cause behavioral abnormalities and psychotic symptoms, including irritability, aggression, anger, anxiety, depression, emotional lability, and hostility. Monitor for new or worsening mood changes, aggression, or suicidal thoughts or behavior, especially after dose changes or in the first weeks of therapy.
When should a nurse hold levetiracetam and call the prescriber or pharmacist?
Hold for known hypersensitivity to levetiracetam, anaphylaxis or angioedema, new rash suggesting serious dermatologic reaction, suspected DRESS, active suicidal intent, orders that omit required renal adjustment when creatinine clearance is reduced, or patient plans to stop abruptly without a taper plan. Do not restart after SJS/TEN or confirmed serious hypersensitivity.
How is levetiracetam dosed in renal impairment?
Adult dosing must be individualized by creatinine clearance adjusted for body surface area per Table 1 in labeling: normal greater than 80 mL/min/1.73 m² uses 500 to 1500 mg every 12 hours; mild 50 to 80 uses 500 to 1000 mg every 12 hours; moderate 30 to 50 uses 250 to 750 mg every 12 hours; severe below 30 uses 250 to 500 mg every 12 hours; ESRD on dialysis uses 500 to 1000 mg every 24 hours with a 250 to 500 mg supplemental dose after dialysis.
Is there an antidote for levetiracetam overdose?
There is no specific antidote for levetiracetam overdose. Management is supportive with airway monitoring and vital signs. Standard hemodialysis clears approximately 50 percent in 4 hours and may be considered based on clinical state or significant renal impairment. Contact local poison control or medical toxicology services per facility protocol.
Can levetiracetam be stopped abruptly?
Labeling states to avoid abrupt withdrawal from levetiracetam to reduce the risk of increased seizure frequency and status epilepticus. Antiepileptic drugs should generally be withdrawn gradually unless a serious adverse reaction requires rapid discontinuation per prescriber direction.
References
-
U.S. National Library of Medicine. LEVETIRACETAM tablet, film coated — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63b36274-89f0-42d8-9f09-f9e78e179af4
-
U.S. Food and Drug Administration. Medication Guides — Keppra (levetiracetam).https://www.fda.gov/drugs/drug-safety-and-availability/medication-guides
-
U.S. National Library of Medicine. Levetiracetam. MedlinePlus.https://medlineplus.gov/druginfo/meds/a699059.html
-
Drugs and Lactation Database (LactMed). Levetiracetam. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM362/
-
U.S. Food and Drug Administration. Suicidal behavior and ideation and antiepileptic drugs.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidal-behavior-and-ideation-and-antiepileptic-drugs
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.